A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
نویسندگان
چکیده
منابع مشابه
A phase II study of iproplatin in advanced or metastatic stomach cancer. The EORTC Early Clinical Trial Group.
INTRODUCTION CISPLATIN has been shown to have some activity in gastric cancer but its application is limited because of toxicity [ 11. In recent years, the search for platinum compounds with reduced toxicity has been the main goal in the development of platinum analogs. Based on available phase I data [2, 31, our group decided to evaluate the antitumor activity of the non-nephroand neurotoxic p...
متن کاملPhase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma.
PURPOSE An earlier phase II trial of paclitaxel in patients with metastatic nasopharyngeal carcinoma (NPC) demonstrated a response rate of 22%. Hence we proceeded to study the combination of paclitaxel and carboplatin in these patients. PATIENTS AND METHODS The 21-day regimen was as follows: i.v. paclitaxel 175 mg/m2 over three hours preceded by standard premedications, followed by i.v. carbo...
متن کاملPaclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
PURPOSE Studies conducted by the Eastern Cooperative Oncology Group (ECOG) indicate both paclitaxel and carboplatin are associated with an improvement in 1-year survival in patients with stage IV non-small-cell lung cancer (NSCLC). Based on these findings, a phase II trial of these agents in combination was conducted in patients with advanced NSCLC. PATIENTS AND METHODS Eligibility included p...
متن کاملPhase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.
BACKGROUND Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensitie...
متن کاملPhase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
BACKGROUND Paclitaxel has shown promising activity in gastric cancer and has synergism with cisplatin. This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel (145 mg/m(2)) plus cisplatin chemotherapy in metastatic or relapsed gastric cancer. METHODS Chemotherapy-naïve patients with metastatic or relapsed gastric cancer were enrolled. Paclitaxel 145 mg/m(2) was a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Lung Cancer
سال: 2005
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2005.05.012